KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Enterprise Value (2016 - 2025)

Biomarin Pharmaceutical's Enterprise Value history spans 17 years, with the latest figure at -$1.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 37.17% year-over-year to -$1.6 billion, compared with a TTM value of -$1.6 billion through Dec 2025, down 37.17%, and an annual FY2025 reading of -$1.6 billion, down 37.17% over the prior year.
  • Enterprise Value for Q4 2025 was -$1.6 billion at Biomarin Pharmaceutical, down from -$1.5 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$930.4 million in Q3 2024, with the low at -$1.6 billion in Q4 2025.
  • Average Enterprise Value over 5 years is -$1.2 billion, with a median of -$1.1 billion recorded in 2023.
  • Year-over-year, Enterprise Value grew 28.31% in 2021 and then crashed 58.83% in 2025.
  • Tracing BMRN's Enterprise Value over 5 years: stood at -$1.0 billion in 2021, then dropped by 27.39% to -$1.3 billion in 2022, then increased by 16.86% to -$1.1 billion in 2023, then fell by 5.95% to -$1.1 billion in 2024, then crashed by 37.17% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Enterprise Value are -$1.6 billion (Q4 2025), -$1.5 billion (Q3 2025), and -$1.4 billion (Q2 2025).